tezosentan has been researched along with lu 135252 in 5 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (lu 135252) | Trials (lu 135252) | Recent Studies (post-2010) (lu 135252) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 196 | 13 | 14 |
| Protein | Taxonomy | tezosentan (IC50) | lu 135252 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.016 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ | 1 |
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Cheng, TO | 1 |
| Lüscher, TF; Spieker, LE | 1 |
| Cheng, G; Li, B; Li, Y; Liu, D; Lu, S; Xiao, J; Yuan, W; Zhao, Z | 1 |
3 review(s) available for tezosentan and lu 135252
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
Will endothelin receptor antagonists have a role in heart failure?
Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome | 2003 |
Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.
Topics: Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension; Middle Aged; Models, Statistical; Phenylpropionates; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Tetrazoles | 2017 |
1 trial(s) available for tezosentan and lu 135252
| Article | Year |
|---|---|
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones | 2004 |
1 other study(ies) available for tezosentan and lu 135252
| Article | Year |
|---|---|
Endothelin receptor blockade in congestive heart failure.
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Phenylpropionates; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2001 |